BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 22654017)

  • 1. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma.
    Mohapatra PR; Punatar S; Prabhash K
    Eur Respir J; 2012 Jun; 39(6):1550-1; author reply 1551. PubMed ID: 22654017
    [No Abstract]   [Full Text] [Related]  

  • 2. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
    Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T
    Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations.
    Yuan S; Yu SL; Chen HY; Hsu YC; Su KY; Chen HW; Chen CY; Yu CJ; Shih JY; Chang YL; Cheng CL; Hsu CP; Hsia JY; Lin CY; Wu G; Liu CH; Wang CD; Yang KC; Chen YW; Lai YL; Hsu CC; Lin TC; Yang TY; Chen KC; Hsu KH; Chen JJ; Chang GC; Li KC; Yang PC
    J Clin Oncol; 2011 Sep; 29(25):3435-42. PubMed ID: 21810691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.
    Heuckmann JM; Rauh D; Thomas RK
    J Clin Oncol; 2012 Sep; 30(27):3417-20. PubMed ID: 22915655
    [No Abstract]   [Full Text] [Related]  

  • 5. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.
    Alam N; Gustafson KS; Ladanyi M; Zakowski MF; Kapoor A; Truskinovsky AM; Dudek AZ
    Clin Lung Cancer; 2010 Sep; 11(5):E1-4. PubMed ID: 20837450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
    Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
    Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
    De Pas T; Toffalorio F; Manzotti M; Fumagalli C; Spitaleri G; Catania C; Delmonte A; Giovannini M; Spaggiari L; de Braud F; Barberis M
    J Thorac Oncol; 2011 Nov; 6(11):1895-901. PubMed ID: 21841502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limitations of single-strand conformation polymorphism analysis as a high-throughput method for the detection of EGFR mutations in the clinical setting.
    Weber F; Fukino K; Villalona-Calero M; Eng C
    J Clin Oncol; 2005 Aug; 23(24):5847-8; author reply 5848-9. PubMed ID: 16110042
    [No Abstract]   [Full Text] [Related]  

  • 9. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
    Chang JW; Liu HP; Hsieh MH; Fang YF; Hsieh MS; Hsieh JJ; Chiu YT; Tsai HY; Chen YH; Chen YT; Hsu HY; Chen YT; Tsai SF; Chen YR; Hsi BL; Huang SF
    Lung Cancer; 2008 Sep; 61(3):328-39. PubMed ID: 18304690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
    Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y
    Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors.
    Ansén S; Bangard C; Querings S; Gabler F; Scheffler M; Seidel D; Saal B; Zander T; Nogová L; Töpelt K; Markert E; Stoelben E; Ernestus K; Thomas RK; Wolf J
    J Thorac Oncol; 2010 Mar; 5(3):407-9. PubMed ID: 20186030
    [No Abstract]   [Full Text] [Related]  

  • 12. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
    Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH
    J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation in lung cancer.
    Toyooka S; Matsuo K; Gazdar AF
    N Engl J Med; 2008 Jun; 358(23):2513; author reply 2514. PubMed ID: 18525051
    [No Abstract]   [Full Text] [Related]  

  • 14. [Relationship between mutations of epidermal growth factor receptor gene and clinicopathologic features of non-small cell lung cancers].
    Wang F; Fu S; Tang T; Deng L; Zhang X; Li YZ; Shao JY
    Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):664-6. PubMed ID: 22321543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
    Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
    J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
    Yagishita S; Horinouchi H; Katsui Taniyama T; Nakamichi S; Kitazono S; Mizugaki H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Sumi M; Shiraishi K; Kohno T; Furuta K; Tsuta K; Tamura T
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):140-8. PubMed ID: 25442336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.
    Masago K; Fujita S; Muraki M; Hata A; Okuda C; Otsuka K; Kaji R; Takeshita J; Kato R; Katakami N; Hirata Y
    BMC Cancer; 2015 Nov; 15():908. PubMed ID: 26572169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients.
    Tibaldi C; Giovannetti E; Vasile E; Boldrini L; Gallegos-Ruiz MI; Bernardini I; Incensati R; Danesi R; Cappuzzo F; Peters GJ; Fontanini G
    J Thorac Oncol; 2011 Feb; 6(2):395-6. PubMed ID: 21252721
    [No Abstract]   [Full Text] [Related]  

  • 20. [Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types].
    Sun MH; Yang F; Shen L; Zhang L; Chen Y; Cai X; Zhu XL; Zhou XY
    Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):655-9. PubMed ID: 22321541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.